Incyte enters into supply and distribution pact with Specialised Therapeutics

Oct. 22, 2021 1:29 AM ETIncyte Corporation (INCY)By: Meghavi Singh, SA News Editor
  • Specialised Therapeutics to partner with Incyte Biosciences International Sarl, the Swiss-based affiliate of Incyte (NASDAQ:INCY) to launch and distribute two new medicines for its haematology and oncology portfolios, tafasitamab, sold as Monjuvi, in the United States and Minjuvi in Europe and pemigatinib, or Pemazyre.
  • Under the terms of the agreement, Incyte will be responsible for the development, manufacture and supply of both products and ST will be responsible for regulatory, distribution and local marketing related activities in Australia, New Zealand and Singapore.
  • Tafasitamab in combination with lenalidomide is approved in the U.S. and Europe for the treatment of certain adult patients with lymphoma.
  • Pemigatinib is approved in the U.S., Europe and Japan for the treatment of certain adult patients with cholangiocarcinoma.

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.